## MAP1S
- **UniProt:** Q66K74 · **batch:** proteostasis-batch-2026-06-14 · **review status:** COMPLETE
- **PN placement:** two ALP rows under `Autophagy substrate selection|Selective autophagy receptor` → `Mitophagy` and `Aggrephagy` ; **PN-node mapping:** type `Mitophagy` `mapped`/ok_for_propagation = GO:0000423 mitophagy (more_specific_than_existing_goa); type `Aggrephagy` `mapped`/ok_for_propagation = GO:0035973 aggrephagy (more_specific_than_existing_goa). Group/class/branch all no_mapping.
- **Consistency:** Review YAML, notes and PN annotation agree on MAP1S as a microtubule-associated protein that bridges the autophagy machinery (LC3/Atg8 + LRPPRC→Parkin) to microtubules and mitochondria. Both PN and review trace this to PMID:21262964. The one mismatch: the review captures this only as the generic GO:0006914 autophagy (TAS), whereas PN projects the two specific children mitophagy and aggrephagy. No contradiction, just a granularity gap. PN's "selective autophagy receptor" framing is slightly stronger than the review's "bridge/adaptor" wording, but compatible.
- **PN story / NEW pressure:** PN asserts mitophagy (GO:0000423) and aggrephagy (GO:0035973) — both verified real terms (OLS) and both more specific than the existing GO:0006914. Mitophagy is well supported (PMID:21262964: LRPPRC link to Parkin, Map1s-KO accumulates defective mitochondria). Aggrephagy is supported by the PN-cited Cancer Research paper (MAP1S enhances autophagy to remove aggresomes/aggregates). Existing GOA has ONLY GO:0006914, so both specifics are genuine ADD opportunities, not over-reaches.
- **Mapping strategy:** This gene does not change either node's status. Both type nodes are correctly `mapped`/ok_for_propagation. Unlike the rejected TOMM20/HSPA8/RAB7A broader-term precedents, here the PN-projected terms are NARROWER than the review's generic autophagy term, so propagation refines rather than over-reaches — consistent with the MAP1S KEY PATTERN (selective-autophagy regulator linking machinery to microtubules/aggregates). Scope is appropriate.
- **Evidence alignment:** Good overlap. The PN-cited "MAP1S enhances autophagy to suppress tumorigenesis" (tandfonline) and the Cancer Research hepatocarcinogenesis paper are the autophagy/aggrephagy basis; the review's autophagy annotation rests on PMID:21262964 (the LC3/LRPPRC bridging paper), which is the mechanistic core for mitophagy. The two PN tumor-suppression papers are NOT in the review references — divergence on the aggrephagy/tumor-suppression evidence specifically.
- **Verdict:** Consistent and biologically sound; PN refines (not over-reaches) the review by proposing two verified specific autophagy children. Both are defensible ADDs over the existing generic GO:0006914.
  **Recommended edits:** [YAML] Add `GO:0000423` mitophagy (involved_in) supported_by PMID:21262964 (LRPPRC/Parkin link; defective-mitochondria accumulation) and `GO:0035973` aggrephagy (involved_in) supported_by the PN-cited tandfonline/Cancer Research MAP1S-autophagy papers — fetch and add those PMIDs to `references` first (verify the tandfonline "MAP1S enhances autophagy to suppress tumorigenesis" PMID and the AACR Cancer Research PMID before citing). [MAP] No mapping-status change needed; both type→GO propagations are correct.